Transgene SA (TNG) - Total Liabilities
Based on the latest financial reports, Transgene SA (TNG) has total liabilities worth €17.09 Million EUR (≈ $19.98 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore TNG long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Transgene SA - Total Liabilities Trend (1997–2025)
This chart illustrates how Transgene SA's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Transgene SA's balance sheet.
Transgene SA Competitors by Total Liabilities
The table below lists competitors of Transgene SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Akebia Ther
NASDAQ:AKBA
|
USA | $343.95 Million |
|
Halla Holdings Corp
KO:060980
|
Korea | ₩1.27 Trillion |
|
Shenzhen Keybridge Communications Co Ltd
SHE:002316
|
China | CN¥625.30 Million |
|
Live Oak Acquisition Corp. V Class A Ordinary Shares
NASDAQ:LOKV
|
USA | $30.19 Million |
|
Sichuan Langsha Holding Ltd
SHG:600137
|
China | CN¥139.62 Million |
|
Papercorea
KO:001020
|
Korea | ₩213.43 Billion |
|
Asia Cement
KO:002030
|
Korea | ₩1.26 Trillion |
|
Bioteque
TWO:4107
|
Taiwan | NT$1.35 Billion |
Liability Composition Analysis (1997–2025)
This chart breaks down Transgene SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See TNG net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Transgene SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Transgene SA (1997–2025)
The table below shows the annual total liabilities of Transgene SA from 1997 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €17.09 Million ≈ $19.98 Million |
-36.63% |
| 2024-12-31 | €26.97 Million ≈ $31.53 Million |
-8.90% |
| 2023-12-31 | €29.61 Million ≈ $34.61 Million |
+3.53% |
| 2022-12-31 | €28.59 Million ≈ $33.43 Million |
-17.42% |
| 2021-12-31 | €34.63 Million ≈ $40.48 Million |
-1.63% |
| 2020-12-31 | €35.20 Million ≈ $41.16 Million |
-29.28% |
| 2019-12-31 | €49.78 Million ≈ $58.20 Million |
-30.71% |
| 2018-12-31 | €71.84 Million ≈ $83.99 Million |
-1.29% |
| 2017-12-31 | €72.78 Million ≈ $85.09 Million |
-4.79% |
| 2016-12-31 | €76.45 Million ≈ $89.37 Million |
+2.86% |
| 2015-12-31 | €74.32 Million ≈ $86.89 Million |
+7.54% |
| 2014-12-31 | €69.11 Million ≈ $80.80 Million |
-0.16% |
| 2013-12-31 | €69.23 Million ≈ $80.93 Million |
+13.70% |
| 2012-12-31 | €60.89 Million ≈ $71.18 Million |
+16.71% |
| 2011-12-31 | €52.17 Million ≈ $60.99 Million |
+30.20% |
| 2010-12-31 | €40.07 Million ≈ $46.84 Million |
+33.11% |
| 2009-12-31 | €30.10 Million ≈ $35.19 Million |
-7.16% |
| 2008-12-31 | €32.42 Million ≈ $37.91 Million |
+86.58% |
| 2007-12-31 | €17.38 Million ≈ $20.32 Million |
+27.54% |
| 2006-12-31 | €13.63 Million ≈ $15.93 Million |
+20.92% |
| 2004-12-31 | €11.27 Million ≈ $13.17 Million |
-0.27% |
| 2003-12-31 | €11.30 Million ≈ $13.21 Million |
-3.20% |
| 2002-12-31 | €11.67 Million ≈ $13.65 Million |
-8.71% |
| 2001-12-31 | €12.79 Million ≈ $14.95 Million |
-2.76% |
| 2000-12-31 | €13.15 Million ≈ $15.37 Million |
+15.22% |
| 1999-12-31 | €11.41 Million ≈ $13.34 Million |
+0.77% |
| 1998-12-31 | €11.33 Million ≈ $13.24 Million |
+19.61% |
| 1997-12-31 | €9.47 Million ≈ $11.07 Million |
-- |
About Transgene SA
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) posi… Read more